Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab.

about

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab.

Item

http://www.wikidata.org/entity/Q43119856

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Upregulation of HLA Class I Ex ...... nti-EGFR Antibody Nimotuzumab.

@en

Upregulation of HLA Class I Ex ...... nti-EGFR Antibody Nimotuzumab.

@nl

type

Item

label

Upregulation of HLA Class I Ex ...... nti-EGFR Antibody Nimotuzumab.

@en

Upregulation of HLA Class I Ex ...... nti-EGFR Antibody Nimotuzumab.

@nl

prefLabel

Upregulation of HLA Class I Ex ...... nti-EGFR Antibody Nimotuzumab.

@en

Upregulation of HLA Class I Ex ...... nti-EGFR Antibody Nimotuzumab.

@nl

P1476

Upregulation of HLA Class I Ex ...... Anti-EGFR Antibody Nimotuzumab

@en

P2093

Ailem Rabasa

http://www.w3.org/2001/XMLSchema#string

Belinda Sánchez-Ramírez

http://www.w3.org/2001/XMLSchema#string

Cristina Garrido

http://www.w3.org/2001/XMLSchema#string

Federico Garrido

http://www.w3.org/2001/XMLSchema#string

Greta Garrido

http://www.w3.org/2001/XMLSchema#string

Lisset Chao

http://www.w3.org/2001/XMLSchema#string

P2860

NLR family member NLRC5 is a transcriptional regulator of MHC class I genes

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.

Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling

Different regulation of MHC class I antigen processing components in human tumors.

The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.

Targeting the EGFR signaling pathway in cancer therapy.

Differential expression and clinical significance of three inflammation-related microRNAs in gangliogliomas

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

P304

595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2017.00595

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Angel Garcia-Lora

P577

2017-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29056908

http://www.w3.org/2001/XMLSchema#string

P932

5635422

http://www.w3.org/2001/XMLSchema#string